SOPHiA GENETICS Advances Blood Cancer Genomic Testing With New Myeloid Solutions
Excerpt from the Press Release:
BOSTON and LAUSANNE, Switzerland, June 1, 2021 /PRNewswire/ — SOPHiA GENETICS, the creator of a global data-sharing network that advances data-driven medicine, today released SOPHiA DDM™ for Blood Cancers, novel blood cancer testing solutions across the entire workflow from setup, genomic testing, and in-house advanced analytics. The solutions target the most relevant DNA variants and RNA fusion genes for blood cancers, and come with SOPHiA DDM™ platform analysis, easing the identification of major biomarkers with secondary and tertiary analyses.
Molecular profiling by next-generation sequencing (NGS) of myeloid tumors has transformed the investigation of pathogenic variants that could cause blood cancers. However, difficulties such as NGS design optimization and implementing bioinformatics for accurate variant calling can still be challenging for new and existing laboratories. SOPHiA GENETICS’ scalable new portfolio is designed to address these challenges and empower labs to confidently and securely identify major biomarkers associated with different blood cancers. The portfolio includes:
- Myeloid Solution – targets the 30 most relevant myeloid cancer genes
- Myeloid Solution Plus – assesses an additional 119 key RNA fusion driver genes RNA
- Extended Myeloid Solution – offers the most comprehensive solution, fully covering over 98 genes
Click the button below to read the entire Press Release:
Discover What Sets TrialStat Apart From Ordinary EDC Platforms
Click the image or button below to explore our eClinical Suite Platform and discover what sets TrialStat apart from competing EDC platforms.
Request Your Demo Today!
From rapid database build through database lock, we deliver consistent quality on-time and on-budget. Ready to upgrade your eClinical toolkit?